The Rheumatological Society of Cyprus clarifies in its announcement that no change is needed at the moment in taking the drug methotrexate, while no new information has come out about this preparation.
It is added that the medication continues to be taken by anyone he needs it with due care, which is explained and reminded by the treating physician at every opportunity, while the report of any worrying symptoms to everyone's Rheumatologist continues and any explanation needed by patients on the subject is correct to contact their rheumatologist .
The specific announcement was made today by the Rheumatological Society of Cyprus, on the occasion of the recent publications in the Press regarding the guidelines of the European Medicines Agency, for the drug methotrexate, which is widely used in Rheumatology.
The Rheumatological Society of Cyprus wishes to inform all patients, who are taking the medicine for rheumatic diseases, their families, but also the whole public, who happened to read these publications that methotrexate is a very important medicine in the therapeutic quiver of the rheumatologist/treatment of several rheumatic diseases and is often a drug & # 8220; anchor & # 8221; with which other antirheumatic drugs are combined to treat these conditions.
“Used”, as he notes, “in Rheumatology since the early 1980s and all Rheumatologists are completely familiar with the drug. Nothing new has been announced about the drug, it is reported.
The caution needed with the use of methotrexate is similar to many other anti-rheumatic drugs and with drugs in general. That is, the doctor or the other health professional explains to the patient his choices, the pros and cons of each treatment and together the decision of the treatment that will be followed is made “.
As explained in the announcement “during this discussion, the patient is informed of any side effects and where possible their frequency. Rheumatology also explains the need to monitor these treatments by regular visits to the Rheumatologist, blood tests where needed and reporting any symptoms of concern to the rheumatologist. “
” The style of this announcement and The general outline of the European Medicines Agency communication is more of a reminder, for health professionals and patients, not to forget the importance of explaining any side effects that may occur, having regular check-ups and blood tests and The medicine is taken correctly, ie once a week “, he adds. , that these “news” were announced, without being validated or explained by people who deal with these drugs on a daily basis, ie the Rheumatologists “.
KYPE
